IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
about
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IL-8 and eNOS polymorphisms pr ...... tic colorectal cancer patients
@en
IL-8 and eNOS polymorphisms pr ...... ic colorectal cancer patients.
@nl
type
label
IL-8 and eNOS polymorphisms pr ...... tic colorectal cancer patients
@en
IL-8 and eNOS polymorphisms pr ...... ic colorectal cancer patients.
@nl
prefLabel
IL-8 and eNOS polymorphisms pr ...... tic colorectal cancer patients
@en
IL-8 and eNOS polymorphisms pr ...... ic colorectal cancer patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
IL-8 and eNOS polymorphisms pr ...... tic colorectal cancer patients
@en
P2093
Alessia Mennitto
Carlo Barone
Concetta Santonocito
Donatella Guarino
Ernesto Rossi
Giovanni Schinzari
Ilaria Bossi
Mariantonietta Di Salvatore
Marta Caporale
Michele Basso
P2860
P304
16887-16898
P356
10.18632/ONCOTARGET.14810
P407
P50
P577
2017-01-25T00:00:00Z